verticillins and Colonic-Neoplasms

verticillins has been researched along with Colonic-Neoplasms* in 4 studies

Other Studies

4 other study(ies) available for verticillins and Colonic-Neoplasms

ArticleYear
Verticillin A increases the BIM
    Biochemical and biophysical research communications, 2021, 08-27, Volume: 567

    ABT-737, a small molecule BH-3 mimetic, is less effective against human colon cancers due to its resistance. Verticillin A is a natural compound, which was previously purified from verticillium-infected mushrooms. Hence, we aimed at overcoming the ABT737 resistance observed in CRC tumors by combining Verticillin A with ABT-737 and figuring out the potential mechanism. In this study, we observed that Verticillin A could sensitize colon cancer to ABT-737-induced cell death through induction of mitochondrial-dependent apoptosis. Verticillin A could significantly increase the BIMEL/MCL-1 ratio to overcome ABT737 resistance through the suppression of the MEK/ERK pathway. In addition, up-regulation of BIM protein levels to activate BAX translocation results in apoptosis induction. Altogether, our work suggested the potential application of Verticillin A as a MEK inhibitor in BH3-mimetic-based therapy.

    Topics: Antineoplastic Agents; Bcl-2-Like Protein 11; Biphenyl Compounds; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Indoles; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Sulfonamides

2021
Verticillin A inhibits colon cancer cell migration and invasion by targeting c-Met.
    Journal of Zhejiang University. Science. B, 2020, Volume: 21, Issue:10

    Verticillin A is a diketopiperazine compound which was previously isolated from Amanita flavorubescens Alk (containing parasitic fungi Hypomyces hyalines (Schw.) Tul.). Here, we initially found, by wound healing assay and Transwell assay in vitro, that verticillin A possesses an inhibitory effect against the migration and invasion of the human colon cancer cell. Subsequently, c-mesenchymal-epithelial transition factor (c-Met) was identified as a molecular target of verticillin A by screening key genes related to cell migration. Verticillin A-mediated c-Met suppression is at the transcriptional level. Further study demonstrated that verticillin A suppressed c-MET phosphorylation and decreased c-MET protein level. In addition, verticillin A inhibited the phosphorylation of c-MET downstream molecules including rat sarcoma (Ras)-associated factor (Raf), extracellular signal-regulated kinase (ERK), and protein kinase B (AKT). Overexpression of Erk partially reversed the verticillin A-mediated anti-metastasis action in the human colon cancer cell. More importantly, verticillin A also inhibited cancer cell metastasis in vivo. Thus, verticillin A can significantly inhibit the migration and invasion of colon cancer cells by targeting c-Met and inhibiting Ras/Raf/mitogen-activated extracellular signal-regulated kinase (MEK)/ERK signaling pathways. Therefore, we determined that verticillin A is a natural compound that can be further developed as an anti-metastatic drug in human cancers.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-raf; ras Proteins; RNA Interference; Wound Healing

2020
H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Aug-15, Volume: 195, Issue:4

    The Fas-FasL effector mechanism plays a key role in cancer immune surveillance by host T cells, but metastatic human colon carcinoma often uses silencing Fas expression as a mechanism of immune evasion. The molecular mechanism under FAS transcriptional silencing in human colon carcinoma is unknown. We performed genome-wide chromatin immunoprecipitation sequencing analysis and identified that the FAS promoter is enriched with H3K9me3 in metastatic human colon carcinoma cells. The H3K9me3 level in the FAS promoter region is significantly higher in metastatic than in primary cancer cells, and it is inversely correlated with Fas expression level. We discovered that verticillin A is a selective inhibitor of histone methyltransferases SUV39H1, SUV39H2, and G9a/GLP that exhibit redundant functions in H3K9 trimethylation and FAS transcriptional silencing. Genome-wide gene expression analysis identified FAS as one of the verticillin A target genes. Verticillin A treatment decreased H3K9me3 levels in the FAS promoter and restored Fas expression. Furthermore, verticillin A exhibited greater efficacy than decitabine and vorinostat in overcoming colon carcinoma resistance to FasL-induced apoptosis. Verticillin A also increased DR5 expression and overcame colon carcinoma resistance to DR5 agonist drozitumab-induced apoptosis. Interestingly, verticillin A overcame metastatic colon carcinoma resistance to 5-fluorouracil in vitro and in vivo. Using an orthotopic colon cancer mouse model, we demonstrated that tumor-infiltrating cytotoxic T lymphocytes are FasL(+) and that FasL-mediated cancer immune surveillance is essential for colon carcinoma growth control in vivo. Our findings determine that H3K9me3 of the FAS promoter is a dominant mechanism underlying FAS silencing and resultant colon carcinoma immune evasion and progression.

    Topics: Animals; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; DNA Methylation; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Fluorouracil; Gene Expression Profiling; Gene Silencing; Genome-Wide Association Study; Histocompatibility Antigens; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Indoles; Inhibitory Concentration 50; Liver; Methylation; Methyltransferases; Mice; Promoter Regions, Genetic; Repressor Proteins; Tumor Escape; Xenograft Model Antitumor Assays

2015
Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3.
    Cancer research, 2011, Nov-01, Volume: 71, Issue:21

    Drug resistance is a major cause of failure in cancer chemotherapy. Therefore, identification and combined use of adjuvant compounds that can overcome drug resistance may improve the efficacy of cancer therapy. We screened extracts of Verticillium species-infected mushrooms for antitumor compounds and identified the compound Verticillin A as an inducer of hepatoma cell apoptosis in vitro and an inhibitor of tumor xenograft growth in vivo. Verticillin A exhibited a potent apoptosis-sensitizing activity in human colon carcinoma cells exposed to TRAIL or Fas in vitro. Furthermore, Verticillin A effectively sensitized metastatic human colon carcinoma xenograft to TRAIL-mediated growth inhibition in vivo. At the molecular level, we observed that Verticillin A induces cell-cycle arrest in the G₂ phase of the cell cycle in human colon carcinoma cells, markedly upregulating BNIP3 in both hepatoma and colon carcinoma cells. Notably, silencing BNIP3 decreased the sensitivity of tumor cells to Verticillin A-induced apoptosis in the absence or presence of TRAIL. We found that the BNIP3 promoter is methylated in both human hepatoma and colon carcinoma cells and tumor specimens. Verticillin A upregulated the expression of a panel of genes known to be regulated at the level of DNA methylation, in support of the concept that Verticillin A may act by demethylating the BNIP3 promoter to upregulate BNIP3 expression. Taken together, our findings identify Verticillin A as a potent apoptosis sensitizer with great promise for further development as an adjuvant agent to overcome drug resistance in human cancer therapy.

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Etoposide; Fas Ligand Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Recombinant Proteins; RNA Interference; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Xenograft Model Antitumor Assays

2011